MedTrace Logo

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

NCT05257512 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-02-14

No results posted yet for this study

Summary

This is a phase I/II, open-label and multi-center study of SY-3505, a third-generation ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer (ALK-positive NSCLC).

Conditions

Interventions

DRUG

SY-3505

The third-generation ALK TKI

Sponsors & Collaborators

  • Shouyao Holdings (Beijing) Co. LTD

    lead OTHER

Principal Investigators

  • Yinghui Sun, PhD · Shouyao Holdings (Beijing) Co. LTD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-26
Primary Completion
2024-04-26
Completion
2024-08-26

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05257512 on ClinicalTrials.gov